Managing and treating gout for the elderly: Challenges and solutions
Main Article Content
Abstract
Gout has long been known as a localized inflammatory arthritis caused by the deposition of urate crystals in the joints and soft tissues. Today, gout is recognized as a systemic metabolic disorder with far-reaching health effects, especially in the elderly. In the context of global population aging, particularly in developing countries, the burden of gout presents new challenges. Through the synthesis of data from the literature and clinical guidelines of international associations (EULAR, ACR), this article focuses on analyzing the pathogenesis, clinical diversity, comorbidities, and safe and effective treatment of elderly gout patients.
Article Details
Keywords
Gout, elderly, comorbidity
References
2. Carter MW, Roman YM. Perspectives on the Epidemiology of Hyperuricemia and Gout in Older Adults. Sr Care Pharm. 2025;40(9):365-372. doi:10.4140/TCP.n.2025.365
3. Bolzetta F, Veronese N, Manzato E, et al. Chronic gout in the elderly. Aging Clin Exp Res. 2013;25(2):129-137. doi:10.1007/s40520-013-0031-z
4. Erratum. Arthritis Care Res. 2021;73(3):458-458. doi:10.1002/acr.24566
5. Russell MD, Rutherford AI, Ellis B, et al. Management of gout following 2016/2017 European (EULAR) and British (BSR) guidelines: An interrupted time-series analysis in the United Kingdom. Lancet Reg Health - Eur. 2022;18:100416. doi:10.1016/j.lanepe.2022.100416
6. Punzi L, Scagnellato L, Galozzi P, et al. Gout: one year in review 2025. Clin Exp Rheumatol. Published online February 19, 2025. doi:10.55563/clinexprheumatol/9sdln5
7. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15(1):123. doi:10.1186/s12916-017-0890-9
8. Habeeb EA, Ghaith AM, Alshehri AM, et al. Revealing the hidden impact of SGLT2 inhibitors on uric acid levels: a retrospective multicenter cohort study. Front Endocrinol. 2025;16:1667438. doi:10.3389/fendo.2025.1667438
9. Pan SY, Cheng RJ, Xia ZJ, et al. Risk of dementia in gout and hyperuricaemia: a meta-analysis of cohort studies. BMJ Open. 2021;11(6):e041680. doi:10.1136/bmjopen-2020-041680
10. Zhou Z, Zhong S, Liang Y, et al. Serum Uric Acid and the Risk of Dementia: A Systematic Review and Meta-Analysis. Front Aging Neurosci. 2021;13:625690. doi:10.3389/fnagi.2021.625690
11. Cha Y, Lee J, Choy W, et al. Pathophysiology and Treatment of Gout Arthritis; including Gout Arthritis of Hip Joint: A Literature Review. Hip Pelvis. 2024;36(1):1-11. doi:10.5371/hp.2024.36.1.1
12. Wüthrich H, Alromaih F, So A. Guidelines for the treatment of gout: a Swiss perspective. Swiss Med Wkly. 2016;146(3536):w14341. doi:10.4414/smw.2016.14341
13. Holladay EE, Mudano AS, Xie F, et al. Real-World Effectiveness of Pegloticase Associated With Use of Concomitant Immunomodulatory Therapy. Arthritis Care Res. 2024;76(10):1361-1370. doi:10.1002/acr.25361
14. Sun Y, Liu W, Li D, et al. Association between frailty and gout in middle-aged and older adults: A nationwide cross-sectional and Mendelian randomization study. Medicine (Baltimore). 2025;104(45):e45794. doi:10.1097/MD.0000000000045794
15. Stamp LK, Chapman PT. Gout and its comorbidities: implications for therapy. Rheumatology. 2013;52(1):34-44. doi:10.1093/rheumatology/kes211
16. Lorenzo JPP, Sollano MaHMZ, Salido EO, et al. 2021 Asia-Pacific League of Associations for Rheumatology clinical practice guideline for treatment of gout. Int J Rheum Dis. 2022;25(1):7-20. doi:10.1111/1756-185X.14266